Royalty Report: Drugs, Disease, cardiac – Collection: 281500


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • cardiac
  • Enzymes

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 281500

License Grant
Under the Filgotinib Amendment Agreement, the Company has greater involvement in filgotinib’s global strategy, and will participate more broadly in the commercialization of the product in Europe, providing the opportunity to build a commercial presence on an accelerated timeline. The Company and Irish Licensee will co-commercialize filgotinib in France, Germany, Italy, Spain and the United Kingdom and retain the 50/50 profit share in these countries that was part of the original filgotinib license agreement dated 16 December 2015, and under the Filgotinib Amendment Agreement, the Company will have an expanded commercial role. The Company retains exclusive rights in Belgium, the Netherlands and Luxembourg, where the 50/50 profit share also applies.
License Property
Filgotinib is a Janus kinase inhibitor with selectivity for subtype JAK1 of this enzyme. It is considered a promising agent as it inhibits JAK1 selectively.  It shows long-term efficacy in the treatment of various inflammatory diseases.

Licensor discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases.

Field of Use
Filgotinib is a drug for the treatment of rheumatoid arthritis and Crohns disease.

IPSCIO Record ID: 341530

License Grant
Under the terms of the new arrangement, Belgium Licensee will assume all development, manufacturing, commercialization and certain other rights for filgotinib in Europe.
License Property
Filgotinib preferential JAK1 inhibitor with a potential best-in-class product profile (Jyseleca). Janus kinases (JAK) are critical components of signaling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in RA. Filgotinib is a preferential JAK1 inhibitor. Jyseleca® is the brand name for filgotinib
Field of Use
Field of Use is for the treatment of IBD (Inflammatory Bowel Disease), CD (Crohns Disease), UC (Ulcerative Colitis) and potentially other inflammatory diseases such as RA (Rheumatiod arthritus).

Inflammatory Bowel Disease (IBD) This is a general term for an autoimmune disease affecting the bowel, including CD and UC. CD affects the small and large intestine, while UC affects the large intestine. Both diseases involve inflammation of the intestinal wall, leading to pain, bleeding, and ultimately, in some cases, surgical removal of part of the bowel.

Crohn’s disease (CD) An IBD involving inflammation of the small and large intestines, leading to pain, bleeding, and ultimately in some cases surgical removal of parts of the bowel.

Ulcerative colitis (UC) An IBD causing chronic inflammation of the lining of the colon and rectum (unlike CD with inflammation throughout the gastrointestinal tract).

Rheumatoid arthritis (RA) A chronic, systemic inflammatory disease that causes joint inflammation, and usually leads to cartilage destruction, bone erosion and disability.

Inflammatory diseases is a large, unrelated group of disorders associated with abnormalities in inflammation.

IPSCIO Record ID: 260445

License Grant
The Parties entered into the License Agreement under which Licensee obtained an exclusive worldwide license under the Licensor Patents, Licensor Knowhow and Joint Patents to develop and commercialize Enoximone.  Licensor also transferred any and all of Licensors rights under the existing Licensors Trademarks in several countries around the world, including the United Kingdom and the Benelux countries.

With the First Amendment to the License Agreement  under which Licensee granted to Licensor the right to co-market the Product containing the oral form of Enoximone (Oral Enoximone) in Europe. This grant was terminated under the Second Amendment to the License Agreement.

The Second Amendment provided for a certain royalty to be paid by Licensee to Licensor in the event the Net Sales of Oral Enoximone in Europe reached or exceeded the threshold set forth in the amendment.

Licensor was acquired by a pharmaceutical company organized under the laws of France.  

The Parties acknowledge and agree that the License Agreement only obligates Licensee to pay Licensor royalties on Net Sales of Perfan i.v. in the Limited European Countries. The Agreement does not obligate Licensee to pay royalties on the Net Sales of Oral Enoximone in the Limited European Countries. The Parties further acknowledge and agree that the License Agreement, as amended and restated, only concerns and relates to the sale of any Product, including Perfan i.v. and Oral Enoximone, in any Territory other than Europe, and only concerns and relates to the sale of any Additional Product  in the Limited European Countries.

Licensor transfer of the Licensor Trademarks in the United Kingdom and the Benelux countries of Belgium, the Netherlands and Luxembourg, is perpetual and irrevocable, as of the Effective Date of the Third Amendment.

License Property
Enoximone is a small organic molecule that exhibits highly selective inhibition of type-III phosphodiesterase, or PDE-III, an enzyme that is present in the heart and plays an important regulatory role in cardiac function.

Perfan® I.V. is an intravenous (i.v.) formulation of enoximone.

Field of Use
Enoximone capsules for the treatment of patients with advanced chronic heart failure.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.